A2025 Acquisitions
Total Consideration
$50.3M
Purchase-Price Allocation
Goodwill
$12.5M
Contingent Earn-Out
$24.1M
Deferred Tax Liability
—
XPEL, INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$2
Book Value Per Share
$10
Free Cash Flow Per Share
$2
Cash Per Share
$2
Revenue Per Share
$17
OCF Per Share
$2
Return on Equity
20.3%
Return on Assets
15.3%
Return on Invested Capital
20.0%
Debt to Equity
—
Current Ratio
3.25
Quick Ratio
1.52
Asset Turnover
1.43
Days Sales Outstanding
38.21
Days Inventory On Hand
162.82
R&D / Revenue
0.6%
SBC / Revenue
0.6%
Capex / Revenue
0.8%
Working Capital
$160M
Net Current Asset Value
$133M
Invested Capital
$280M
OCF / Net Income
1.31
FCF / Net Income
1.23
Accruals Ratio (Sloan)
-4.1%
Net Debt
$-51M
Net Debt / EBITDA
-0.74
Interest Coverage
754.81
Cash Coverage
806.48
Capex Coverage
16.70
Tangible Common Equity
$171M
TCE / Total Assets
44.8%
Goodwill / Total Assets
15.5%
NOPAT
$50M
Cash ROIC
24.9%
WC / Revenue
33.5%
Capex / D&A
0.64
Reinvestment Rate
38.2%
Total Payout Ratio
5.9%
Asset Growth vs Revenue Growth
20.7%
Revenue 5Y CAGR
24.5%
EPS 5Y CAGR
22.9%
FCF 5Y CAGR
30.4%
EBITDA 5Y CAGR
22.8%
Book Value 5Y CAGR
39.3%
Stock Price (FY-end)
$50
Market Cap
$1.38B
P/E Ratio
26.97
P/S Ratio
2.90
P/B Ratio
4.93
P/TB Ratio
8.06
P/OCF Ratio
20.64
P/FCF Ratio
21.96
Enterprise Value
$1.33B
EV / EBITDA
19.31
EV / Sales
2.79
EV / FCF
21.15
FCF Yield
4.6%
Shareholder Yield
0.0%
Buyback Yield
0.2%
R&D Yield
0.2%
Capex Yield
0.3%
Operating Leverage
0.45
Graham Number
$21
Shares Variation (YoY)
0.1%
Beta (5Y)
1.29
Cost of Equity
11.0%
Cost of Debt (after tax)
—
52W High
$53
52W Low
$25
Trailing Return 1Y
25.9%
Trailing Return 5Y
-3.1%
F-Score (Piotroski)
4.00
Z-Score (Altman)
11.77
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Beat / Miss vs Estimate
Stock Price on Earnings Dates
XPEL, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | — | 2.00% | 1.60% | 0.90% |
| Foreign Rate Differential | — | — | — | 0.30% | -0.20% | 2.20% |
| Other Adjustments | — | — | — | -0.60% | 0.20% | -0.80% |
| Nondeductible Expenses | — | — | — | 0.30% | 0.70% | 0.60% |
| Valuation Allowance Change | — | — | — | 0.00% | 0.00% | 0.00% |
| Tax Law Change | — | — | — | 0.00% | 0.00% | 0.00% |
| Effective Tax Rate | — | — | — | 20.20% | 19.90% | 19.50% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $4.5M | $7.9M | $10.6M | $13.2M | $11.3M | $12.5M |
| Income Taxes Paid (Cash) | $4.5M | $7.8M | $9.9M | $15.3M | $13.6M | $12.5M |
XPEL, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
A2023 Acquisitions
Total Consideration
$20.8M
Purchase-Price Allocation
Goodwill
$10.4M
Contingent Earn-Out
—
Deferred Tax Liability
$1.5M
A2024 Acquisitions
Total Consideration
$12.5M
Purchase-Price Allocation
Goodwill
$7.6M
Contingent Earn-Out
$1.6M
Deferred Tax Liability
$679.0K